德琪医药塞利尼索15项研究及成果将在2021 ASCO公布

2021-06-02 18:55   来源: 中华健康新闻网    阅读次数:4092

致力于研发和商业化创新肿瘤疗法的领先生物制药公司——德琪医药有限公司(简称“德琪医药”,香港联交所股票代码:6996.HK)今日宣布,同类首款选择性核输出抑制剂——塞利尼索(selinexor)15项研究及成果将在2021年美国临床肿瘤学大会(ASCO)年会上公布。此届 ASCO 会议于6月4日至6月8日在线上召开。


线上摘要

Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).

摘要编号:8027

Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone(Vd) in patients with previously treated multiple myeloma.

摘要编号:8024

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

摘要编号:8019

Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.

摘要编号:e19037

Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dosedexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

摘要编号:e20002

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

摘要编号:8018

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.

摘要编号:TPS5610

Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.

摘要编号:e15579

A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.

摘要编号:TPS2071

A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.

摘要编号:11534

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

摘要编号:5565

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

摘要编号:8038

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

摘要编号:TPS8055

Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).

摘要编号:11509

Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).

摘要编号:e20020

关于德琪医药

德琪医药有限公司(简称“德琪医药”,香港联交所股票代码:6996.HK)是一家以研发为驱动的生物制药领先企业,致力于为亚太乃至全球患者提供最领先的疗法,治疗肿瘤及其他危及生命的疾病。自2017年正式运营以来,德琪医药通过合作引进和自主研发,建立了一条从临床前到临床阶段不断延展的丰富产品管线。目前,德琪医药已在多个亚太市场获得15个临床批件(IND),并递交了5个新药上市申请(NDA)。德琪医药将以“医者无疆,创新永续”为愿景,专注于同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化,解决亟待满足的临床需求。


责任编辑:赵硕
分享到:
0
【慎重声明】凡本站未注明来源为"中华健康新闻网"的所有作品,均转载、编译或摘编自其它媒体,转载、编译或摘编的目的在于传递更多信息,并不代表本站赞同其观点和对其真实性负责。如因作品内容、版权和其他问题需要同本网联系的,请在30日内进行!